胃肠道恶性肿瘤患者的肿瘤相关胰蛋白酶抑制剂、癌胚抗原及急性期反应蛋白CRP和α1-抗胰蛋白酶

Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.

作者信息

Solakidi Sylvia, Dessypris Athanassios, Stathopoulos George P, Androulakis George, Sekeris Constantine E

机构信息

Institute of Biological Research, National Hellenic Research Foundation, 116 35 Athens, Greece.

出版信息

Clin Biochem. 2004 Jan;37(1):56-60. doi: 10.1016/j.clinbiochem.2003.09.002.

DOI:10.1016/j.clinbiochem.2003.09.002

PMID:14675563

Abstract

OBJECTIVES

Elevated serum tumour-associated trypsin inhibitor (TATI) levels have been observed in association with malignancy or inflammation. The aim of our study was to evaluate the role of TATI in gastric and colorectal cancer.

DESIGN AND METHODS

In preoperative serum samples, we measured TATI, carcinoembryonic antigen (CEA), C-reactive protein (CRP) and alpha(1)-antitrypsin (AAT).

RESULTS

Elevated levels of TATI were observed in 50% and 41.7% of patients with gastric and colorectal cancer. Elevated levels of TATI were observed only in 8% of patients with benign gastrointestinal malignancies (92% specificity). Elevated levels of CEA were observed in 25% and 24.4% of patients, respectively. The total positivity of CEA and TATI (with at least one marker positive) was 62.5% and 57%, respectively. Spearman's test has shown a statistically significant correlation among serum TATI, CRP and AAT levels (P < 0.01).

CONCLUSIONS

In gastrointestinal cancer, TATI can be used as a complementary tumour marker in addition to CEA. Regulation of TATI synthesis resembles that of acute-phase reactant proteins.

摘要

目的

血清肿瘤相关胰蛋白酶抑制剂（TATI）水平升高与恶性肿瘤或炎症相关。本研究旨在评估TATI在胃癌和结直肠癌中的作用。

设计与方法

在术前血清样本中，我们检测了TATI、癌胚抗原（CEA）、C反应蛋白（CRP）和α1抗胰蛋白酶（AAT）。

结果

胃癌和结直肠癌患者中分别有50%和41.7%的患者TATI水平升高。仅8%的良性胃肠道恶性肿瘤患者TATI水平升高（特异性为92%）。CEA水平升高的患者分别为25%和24.4%。CEA和TATI的总阳性率（至少一项指标阳性）分别为62.5%和57%。Spearman检验显示血清TATI、CRP和AAT水平之间存在统计学显著相关性（P<0.01）。